Studies indicate that infliximab, a TNFα blocker, can increase the risk of leukemia and lymphoma, possibly by reducing T-cell recognition of cancer cells and increasing the risk of tumor cell proliferation and metastasis9. This evidence concerns the gene TNF and neoplasm.